Rosacea Medication

  • Author: Agnieszka Kupiec Banasikowska, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: May 31, 2011
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Topical metronidazole is commonly used as a first-line agent. Topical azelaic acid, sulfacetamide products, and topical acne medications are also commonly used. Retinoids are advocated by some authorities.[15, 16, 17]

In addition to the agents listed below, anecdotal evidence indicates effective treatment of rosacea with medications that reduce flushing, including beta-blockers, clonidine, naloxone, ondansetron, and selective serotonin reuptake inhibitors.

Oral contraceptive therapy has been helpful in patients who provide historical information of worsening rosacea with their hormonal cycle.

Dapsone has been used in severe, refractory rosacea, and dapsone has been particularly beneficial for patients who cannot take isotretinoin.[18]

Next

Immunosuppressants

Class Summary

These agents inhibit immune reactions resulting from diverse stimuli.[19]

Tacrolimus ointment (Protopic)

 

Reduces itching and inflammation by suppressing release of cytokines from T cells. Also inhibits transcription of genes encoding IL-3, IL-4, IL-5, GM-CSF, and TNF-alpha, all of which are involved in early stages of T-cell activation. Additionally, may inhibit release of preformed mediators from skin mast cells and basophils, and may down-regulate expression of FCeRI on Langerhans cells. Can be used in patients as young as 2 y. Drugs of this class are more expensive than topical corticosteroids. Available as ointment in concentrations of 0.03% and 0.1%. Indicated only after other treatment options have failed.

Previous
Next

Antibiotics

Class Summary

Since the 1950s, oral antibiotics have been prescribed off label for treatment because microorganisms were thought to be the underlying cause of disease. In current practice, experts do not believe bacterial infection plays a part in the pathogenesis of rosacea; however, the observed clinical benefits of oral antibiotics have allowed this treatment option to remain in favor for both physicians and patients. Since 2006, nonantibiotic dosing of doxycycline has become first-line treatment for many clinicians. In many cases, oral and topical antibiotics are used in combination; the oral treatment is eventually withdrawn and the topical treatment is used alone as maintenance therapy.[18]

In patients who require a systemic antibiotic, evidence suggests that the newer regimen of 40 mg of doxycycline is as effective as the older regimen of 100 mg of doxycycline[20] For many patients, this could represent a significant cost reduction.

Metronidazole gel 0.75% or 1% (MetroGel, Noritate, Flagyl, Protostat)

 

Imidazole ring–based antibiotic active against various anaerobic bacteria and protozoa.

Oral metronidazole has been shown to be beneficial against papules and pustules of acne rosacea.

Topical applications are helpful for mild disease and as an adjuvant to systemic therapy.

Erythromycin (E.E.S., E-Mycin, Eryc, Ery-Tab) tab or 2% topical solution

 

Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections.

In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be taken q12h. For more severe infections, double the dose.

Can be used when tetracyclines are not tolerated or are contraindicated.

Used for the treatment of ocular rosacea.

Fusidic acid (Fucithalmic)

 

Ophthalmic susp as 10 mg/g (1%) (0.2 g) unit-dose, without preservative; 3 g and 5 g in multidose contains benzalkonium chloride.

For the treatment of ocular rosacea. Topical antibacterial that inhibits bacterial protein synthesis, causing bacterial death. Rosacea may respond to topical fusidic acid for at least 3 mo.

Clindamycin topical

 

Semisynthetic antibiotic produced by 7(S)-chloro substitution of 7(R)-hydroxyl group of parent compound lincomycin. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Widely distributes in body without penetration of CNS. Protein bound and excreted by liver and kidneys.

Upon application to skin, drug is converted to active component, which inhibits the microorganism.

Available as topical solution, lotion, or gel for external use. Solution contains equivalent of 10 mg/mL clindamycin.

Effective against mild-to-moderate papulopustular rosacea.

Tetracycline (Sumycin)

 

Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s). Has anti-inflammatory activity. Improvement is evident within 2-4 mo after commencement of therapy.

Minocycline (Dynacin, Minocin, Solodyn)

 

Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible P acnes. The extended-release tablet (Solodyn) has a variety of doses ranging from 45 mg up to 135 mg and can be administered once daily.

Doxycycline (Oracea, Bio-Tab, Doryx, Periostat, Vibramycin)

 

Broad-spectrum, synthetically derived, bacteriostatic antibiotic in tetracycline class. Almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations.

Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. May block dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Clarithromycin (Biaxin)

 

Semisynthetic macrolide antibiotic that reversibly binds to P site of 50S ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis by stimulating dissociation of peptidyl tRNA from ribosomes, causing bacterial growth inhibition.

Previous
Next

Retinoids

Class Summary

These agents decrease the cohesiveness of abnormal hyperproliferative keratinocytes and may reduce the potential for malignant degeneration. They modulate keratinocyte differentiation, and they have been shown to reduce the risk of skin cancer formation in patients who have undergone renal transplantation.

Tretinoin topical (Avita, Retin-A, Retin-A Micro)

 

Structurally related to vitamin A. May be helpful for recalcitrant disease, but recurrence is common. Long-term, low-dose therapy may be suitable for selected patients.

May cause skin irritation in some patients. Has been linked to promotion of angiogenesis; however, has not demonstrated increased telangiectasias.

Inhibits microcomedo formation and eliminates lesions. Makes keratinocytes in sebaceous follicles less adherent and easier to remove. Available as 0.025%, 0.05%, and 0.1% creams. Available also as 0.01% and 0.025% gels.

Isotretinoin (Accutane)

 

Oral agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). May be helpful for recalcitrant disease, but recurrence is common. Long-term, low-dose therapy may be suitable for selected patients.

A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.

Previous
Next

Corticosteroids

Class Summary

These agents are relatively contraindicated, except as a short course in rosacea fulminans.

Prednisolone (AK-Pred, Delta-Cortef, Articulose-50, Econopred)

 

Moderately high doses may be helpful in rosacea fulminans. Decreases inflammation by suppressing migration of PMN leukocytes and reducing capillary permeability. Use in combination with isotretinoin. Rosacea fulminans is treated with moderately high doses of prednisolone (30-60 mg/d) followed by oral isotretinoin.

Previous
Next

Antihypertensive agents

Class Summary

Potassium-sparing diuretics can be used to reduce morbidity.

Spironolactone (Aldactone)

 

Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.

Aldosterone inhibitors help block the renin-angiotensin system and help prevent potassium loss in distal tubules. The body conserves potassium, and less oral potassium supplementation is needed.

Previous
Next

Acne Products

Class Summary

Some products in this category can be effective in patients with papules, pustules, and the phymatous and glandular types of rosacea.

Benzoyl peroxide (Benoxyl, Benzac, Oxy-5, Fostex)

 

Free-radical oxygen is released upon administration and oxidizes bacterial proteins in sebaceous follicles, decreasing quantity of irritating free fatty acids and of anaerobic bacteria. Converted on skin into benzoic acid, which has keratolytic and comedolytic effects. However, can be quite irritating in patients with barrier dysfunction and can cause further erythema. Available over the counter and by prescription.

Available in 2.5%, 5%, and 10% gels, lotions, creams, or washes.

Azelaic acid (Azelex, Finacea)

 

Available in 2 strengths azelaic acid 15% gel (Finacea) or azelaic acid 20% cream (Azelex). Effective against mild-to-moderate papulopustular rosacea. Can be used twice daily as initial treatment. May reduce production of ROS by neutrophils. Some patients report transient burning or stinging.

Sodium sulfacetamide and sulfur (Plexion, Clenia, Rosanil wash, Rosula gel or wash, Rosac cream, Sulfacet-R lotion, Clarifoam EF)

 

Contains 5% sulfur and 10% sodium sulfacetamide. Used topically for acne rosacea. Sodium sulfacetamide has antibacterial properties, whereas sulfur is considered an antiseptic with keratolytic action.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Agnieszka Kupiec Banasikowska, MD  Consulting Staff, Georgetown Dermatology, PLLC

Agnieszka Kupiec Banasikowska, MD is a member of the following medical societies: American Academy of Dermatology and European Academy of Dermatology and Venereology

Disclosure: Nothing to disclose.

Coauthor(s)

Saurabh Singh, MD  Staff Physician, Department of Dermatology, Georgetown University/Washington Hospital Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Franklin Flowers, MD  Chief, Division of Dermatology, Professor, Department of Medicine and Otolaryngology, Affiliate Associate Professor of Pediatrics and Pathology, University of Florida College of Medicine

Franklin Flowers, MD, is a member of the following medical societies: American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

Richard P Vinson, MD  Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Christen M Mowad, MD  Associate Professor, Department of Dermatology, Geisinger Medical Center

Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Bamford JT, Gessert CE, Renier CM. Measurement of the severity of rosacea. J Am Acad Dermatol. Nov 2004;51(5):697-703. [Medline].

  2. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. Sep 2004;51(3):327-41; quiz 342-4. [Medline].

  3. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. Sep 2004;74(3 Suppl):21-7, 32-4. [Medline].

  4. Laquer V, Hoang V, Nguyen A, Kelly KM. Angiogenesis in cutaneous disease: part II. J Am Acad Dermatol. Dec 2009;61(6):945-58; quiz 959-60. [Medline].

  5. Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol. Mar 1993;28(3):443-8. [Medline].

  6. Tisma VS, Basta-Juzbasic A, Jaganjac M, et al. Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol. Feb 2009;60(2):270-6. [Medline].

  7. Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthetic Derm. Jan 2009;2(1):26-30.

  8. Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res. Oct 18 2005;10(10):454-6. [Medline].

  9. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. Aug 2008;122(2):261-6. [Medline].

  10. Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol. Mar 2000;42(3):468-72. [Medline].

  11. Greaves MW, Burova E. Flushing: causes, investigation and clinical consequences. J Eur Acad Dermatol Venereol. 1997;8:91-100.

  12. Higgins E, du Vivier A. Alcohol intake and other skin disorders. Clin Dermatol. Jul-Aug 1999;17(4):437-41. [Medline].

  13. Powell FC. Clinical practice. Rosacea. N Engl J Med. Feb 24 2005;352(8):793-803. [Medline].

  14. Lonne-Rahm S, Nordlind K, Edstrom DW, Ros AM, Berg M. Laser treatment of rosacea: a pathoetiological study. Arch Dermatol. Nov 2004;140(11):1345-9. [Medline].

  15. Ceilley RI. Advances in the topical treatment of acne and rosacea. J Drugs Dermatol. Sep-Oct 2004;3(5 Suppl):S12-22. [Medline].

  16. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. Mar 1994;130(3):319-24. [Medline].

  17. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. May 2005;19(3):273-85. [Medline].

  18. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. Mar 2007;12(2):1-5, 9. [Medline].

  19. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol. Feb 2005;152(2):396-9. [Medline].

  20. van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z. Interventions for rosacea. Cochrane Database Syst Rev. Mar 16 2011;3:CD003262. [Medline].

Previous
Next
 
Acne rosacea. Courtesy of Dirk Elston, MD.
Pustular rosacea. Courtesy of Dirk Elston, MD.
Histopathology of rosacea. Perifollicular chronic inflammation and vascular ectasia. Courtesy of Dirk Elston, MD.
Lupus miliaris disseminatus faciei. Courtesy of Dirk Elston, MD.
Caseating granuloma in lupus miliaris disseminatus faciei. Courtesy of Dirk Elston, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.